A Descriptive Safety Study Based on Data Collected From Women and Their Offspring Exposed to Nexviazyme/Nexviadyme (Avalglucosidase Alfa-ngpt/Avalglucosidase Alfa) During Pregnancy and/or Lactation in the Postmarketing Setting
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Avalglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Sponsors Sanofi
Most Recent Events
- 27 Feb 2023 New trial record